AU2002346373A1 - Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies - Google Patents

Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies

Info

Publication number
AU2002346373A1
AU2002346373A1 AU2002346373A AU2002346373A AU2002346373A1 AU 2002346373 A1 AU2002346373 A1 AU 2002346373A1 AU 2002346373 A AU2002346373 A AU 2002346373A AU 2002346373 A AU2002346373 A AU 2002346373A AU 2002346373 A1 AU2002346373 A1 AU 2002346373A1
Authority
AU
Australia
Prior art keywords
adcc
therapies
anti
combination
cell lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002346373A
Inventor
Nabil Hanna
Kandasamy Hariharan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idec Pharmaceuticals Corp
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US33118701P priority Critical
Priority to US60/331,187 priority
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Priority to PCT/US2002/036226 priority patent/WO2003039486A2/en
Publication of AU2002346373A1 publication Critical patent/AU2002346373A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
AU2002346373A 2001-11-09 2002-11-12 Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies Abandoned AU2002346373A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US33118701P true 2001-11-09 2001-11-09
US60/331,187 2001-11-09
PCT/US2002/036226 WO2003039486A2 (en) 2001-11-09 2002-11-12 Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies

Publications (1)

Publication Number Publication Date
AU2002346373A1 true AU2002346373A1 (en) 2003-05-19

Family

ID=23292946

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002346373A Abandoned AU2002346373A1 (en) 2001-11-09 2002-11-12 Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies

Country Status (2)

Country Link
AU (1) AU2002346373A1 (en)
WO (1) WO2003039486A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005282440A1 (en) * 2004-09-08 2006-03-16 Genentech, Inc. Methods of using death receptor ligands and CD20 antibodies
WO2008081942A1 (en) * 2007-01-05 2008-07-10 The University Of Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
CN102076355B (en) 2008-04-29 2014-05-07 Abbvie公司 Dual varistructure domain immunoglobulins and uses thereof
RU2010153580A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Immunoglobulins with two variable domains and their application
SG191625A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2729949A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
AR075798A1 (en) 2009-03-05 2011-04-27 Abbott Lab Binding proteins IL-17 (interleukin 17)
BR112012004710A2 (en) 2009-09-01 2016-08-16 Abbott Lab double variable domain immunoglobulins and their use
HUE029197T2 (en) 2009-09-29 2017-02-28 F Hoffmann-La Roche Ag Pre-filtration adjustment of buffer solutes for high concentration immunoglobulin preparation
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
ES2635594T3 (en) 2010-05-14 2017-10-04 Abbvie Inc. IL-1 binding proteins
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
UY33543A (en) 2010-08-03 2012-02-29 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
CN103260639A (en) 2010-08-26 2013-08-21 Abbvie 公司 Dual variable domain immunoglobulins and uses thereof
AU2011361720B2 (en) 2010-12-21 2017-04-27 Abbvie Inc. IL-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
AR088513A1 (en) 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes directed against sclerostin
TW201333035A (en) 2011-12-30 2013-08-16 Abbvie Inc Dual specific binding proteins directed against IL-13 and/or IL-17
CN104583235B (en) 2012-06-08 2019-03-01 苏特罗生物制药公司 The antibody of the Unnatural amino acid residues containing site-specific, its preparation and application
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
BR112015004022A2 (en) 2012-08-31 2019-09-03 Sutro Biopharma Inc modified amino acids comprising an azido group
UY35110A (en) 2012-11-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins anti-vegf / Dll4 and uses thereof
MX2015013166A (en) 2013-03-15 2015-12-11 Abbvie Inc Dual specific binding proteins directed against il-1 beta and il-17.
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
JP2018535204A (en) 2015-11-02 2018-11-29 ファイブ プライム セラピューティクス, インコーポレイテッド CD80 extracellular domain polypeptides and their use in cancer therapy
US20190177404A1 (en) 2016-06-15 2019-06-13 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019706A1 (en) * 1996-11-08 1998-05-14 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
CN1407901A (en) * 1999-11-08 2003-04-02 Idec药物公司 Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
AU2001287291B2 (en) * 2000-03-31 2006-08-10 Biogen Idec Inc. Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma

Also Published As

Publication number Publication date
WO2003039486A2 (en) 2003-05-15
WO2003039486A3 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
DE60137542D1 (en) Active substances with delayed release containing multiple substances
DE69938591D1 (en) Absorbent disposable articles with enzyme inhibitors containing body care
DE60031419D1 (en) Compositions and methods for improved cell culture
DE60331153D1 (en) Reboxetin containing tablet with delayed active ingredients
SI2803367T1 (en) Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
AU2002236518A1 (en) Recombinant anti-CD30 antibodies and uses thereof
IL170291A (en) Aminoheteroaryl compounds and use thereof in the preparation of medicaments for treating abnormal cell growth
AU2003220424A1 (en) Adipose stromal stem cells for tissue and vascular modification
AU5461699A (en) Methods and reagents for preserving RNA in cell and tissue samples
AU2003297552A8 (en) Enzyme immobilization for use in biofuel cells and sensors
AU2111199A (en) Benzenesulfonamides and benzamides as therapeutic agents
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
AU2002321491A1 (en) Pack containing medicament and dispensing device
AU2003239159A1 (en) Placental derived stem cells and uses thereof
AU2274201A (en) Compounds and compositions for delivering active agents
AUPS244802A0 (en) Fuel cell system
AU2002309661A1 (en) Carton with improved dispenser and handle
AU2002315857A1 (en) Cell proliferation inhibitors containing anti-glypican 3 antibody
AU3079799A (en) Protease inhibitors in absorbent articles
AU2003298514A1 (en) Methods and compositions using cholinesterase inhibitors
GB2394597B (en) Electrode catalyst layer for fuel cell
AU2002319054A1 (en) Multipotent stem cells from peripheral tissues and uses thereof
DE50214416D1 (en) Reproduction of viruses in cell culture
BR0014959B1 (en) electrode for one lithium battery and lithium battery.
DE60114209D1 (en) Medicament forming with a cell regulating factor and / or a promoter for prolifering cells

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase